the results suggest that leukemia patients with mild hepatic dysfunction receiving a combination of full-dose doxorubicin and cytosine arabinoside for acute leukemia will have the same plasma pharmacokinetics , incidence of toxicity , and complete response rate as those with normal hepatic function .
C0023418
patients
C0010711
cytosine arabinoside